Summary
Pooled data from RECLAIM 1 and 2 found that a new combination of antibiotics, incorporating ceftazidime plus avibactam plus metronidazole, was noninferior to meropenem in patients with complicated intra-abdominal infections, with no known safety signals. At the dose studied, the combination was less effective than meropenem to patients with renal impairment at baseline; however, new dosing recommendations are likely to remediate this.
- ceftazidime
 - avibactam
 - metronidazole
 - meropenem
 - intra-abdominal infections
 - renal impairment
 - resistance
 - RECLAIM 1 and 2
 - infectious diseases clinical trials
 - bacterial infections
 
- © 2015 SAGE Publications
 










